Clinical trials
catalyst calendar across sponsors →Studies where KMTS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 observational · 2 with posted results
Held by 5 tracked-famous managers (Point72 Asset Management, L.P., Schonfeld Strategic Advisors LLC, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, AQR CAPITAL MANAGEMENT LLC) · FINRA short interest 10.2 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)NCT05135403observationalOverall shock conversion rate | — | Recruiting | Device: Defibrillation | Sudden Cardiac Arrest | 5,179 | 2025-10-01 | 2025-09-02 |
| ASSURE WCD Clinical Evaluation - Conversion Efficacy StudyNCT04132466results2024-04-05Cumulative First and Second Shock VT/VF Conversion RateOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system | Death, Sudden, Cardiac | 13 | 2020-03-19actual | 2024-04-05 |
| ASSURE WCD Clinical Evaluation - Detection and Safety StudyNCT03887052results2023-10-26WCD False Positive Alarm RateOpen-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: ASSURE™ Wearable Cardioverter Defibrillator (WCD) | Cardiac Arrest, Sudden | 130 | 2019-06-18actual | 2024-03-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19